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Abstract 
 
Conventional chemotherapy is associated with poor outcomes in metastatic renal cell 
carcinoma (RCC). Advances in the understanding of tumor molecular biology and the 
implementation of new drugs that target these molecular pathways have increased the 
arsenal against advanced RCC and improved outcomes in these patients. Herein, we briefly 
describe the latest data on targeted therapies used in the treatment of advanced renal cell 
carcinoma. Search strategy was performed according to PRISMA guidelines. Abstracts of 
relevant studies published in PubMed between 2000 and 2014 were analyzed by two 
authors. Abstracts were selected if they were published in English, data reported was of 
phase II or III clinical trials, and outcomes followed FDA approval.  If consensus between 
the two authors was achieved, they were included in the review. Key words used were 
“target therapy” and “metastatic renal cell carcinoma”. The results of the studies analyzed 
in this review support the benefits of targeted therapy in metastatic RCC. These include 
improved progression-free survival, overall survival, and quality of life as well as reduced 
toxicities compared to immunotherapy. The improvement in outcomes in metastatic RCC 
makes these drugs a preferred option as a primary treatment for these patients. Copyright: 
The Authors. 
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Introduction 
 
 
Renal cell carcinoma (RCC) represents 2-
3% of all cancers, with highest incidence 
occurring in the Western countries (1, 2).  
In the last two decades, its incidence has 
been steadily increasing (1). Although a 
higher incidence of small renal masses are 
being detected, approximately one third of 
the patients still have metastatic disease at 
diagnosis (3, 4). Only a small subset of 
patients have chosen the historical use of 
immunotherapy including interleukin-2 (IL-
2) and interferon alpha (IFN-α) in the 
treatment of advanced RCC. These patients 
have a 5-year survival rate of 6% (5, 6). The 
moderate efficacy of immunotherapy was 
also confirmed by a Cochrane meta-
analysis using 42 studies (7).  
Recently, new drugs have emerged in the 
arsenal of systemic therapy for advanced 
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RCC (Figure 1). A better understanding of 
the molecular signaling  that governs 
tumor growth and progression has led to 
the development of molecular therapies 
targeting the vascular endothelial growth 
factor (VEGF) and mammalian target of 
rapamycin (mTOR) pathways, resulting in 
significant improvement in overall survival 
and quality of life (3). The objective of this 
systematic review is to briefly describe the 
latest data regarding targeted therapies 
used in the treatment of advanced renal 
cell carcinoma.  
Methods  
Search Strategy and Study Selection  
Search strategy and study selection were 
performed according to the Preferred 
Reporting Items for Systematic Reviews 
and Meta-Analysis (PRISMA) guidelines.  
Abstracts of relevant studies and clinical 
trials from PUBMED/MEDLINE (2000 to 
2014) were analyzed by two authors and 
were included if both agreed with the 
selection. A third author was consulted 
when the two authors disagreed. After 
abstract selection, all manuscripts were 
revised and were only included if it met the 
selection criteria and if consensus was 
achieved by the authors.  
The key words used were “target therapy” 
and “metastatic renal cell carcinoma”.  The 
terms identified included names of 
following therapies: Sunitinib, Sorafenib, 
Pazopanib, Axitinib, Cediranib, Everolimus, 
Temsirolimus, Bevacizumab, and Erlotinib.  
Study inclusion criteria included 
contemporary articles published in English 
after 2000 that reported data of phase II 
and III Clinical Trials and outcomes 
followed FDA approval. A total of 40 studies 
were eligible for review. 
Data Extraction and Analysis 
Variables collected from eligible studies 
were: study name, period of the study, 
molecular targets of the drug, FDA 
approval status, indication of treatment, 
recommended dosage of the drug, and 
safety and efficacy of the drug.  Efficacy 
was evaluated by the Overall survival (OS), 
progression free survival (PFS), and time to 
progression (TTP) as defined by the FDA 
Center for Drug Evaluation and Research.  
Safety was evaluated by the severity of 
adverse events defined by the Common 
Toxicity Criteria (CTC).  
Evidence synthesis  
VEGF Targeted Therapies 
Angiogenesis is critical for tumor growth 
and progression, especially in solid tumors 
with vast vascularization such as RCC. 
Vascular endothelial growth factor and its 
receptor (VEGF/VEGFR) mediate VEGFR 
regulation of vessel permeability, 
endothelial cell activation, survival, 
proliferation, invasion, and migration. 
VEGFR and PDGFR pathways exhibit 
tyrosine kinase activity and activate 
downstream signaling pathways as the 
Raf/MEK/ERK (8). During angiogenesis, 
Raf is key in regulating endothelial cell 
survival by controlling  apoptosis pathways 
(9).  Several drugs have been developed to 
target this pathway and control tumor 
angiogenesis. A list of novel therapeutics 
targeting the angiogenesis/VEGF pathway 
is summarized in Table 1.  
Sorafenib  
Sorafenib is an oral multi-tyrosine kinase 
inhibitor with activity against Raf-1 
serine/threonine kinase, B-Raf, vascular 
endothelial grow factor receptor 2 (VGEFR-
2), PDGFR, and c-kit. A phase III trial 
(TARGET trial) showed a significantly 
longer PFS with sorafenib compared to 
placebo (5.5 vs. 2.8 months; p < 0.001). 
Moreover, partial responses were 
significantly higher (10%) in those patients 
treated with sorafenib compared to 2% of 
those treated with placebo (P<0.001). Cross 
over was performed in patients of the 
placebo group which presented a reduced 
risk of death. 16 months after crossover, 
the overall survival in the sorafenib treated 
cohort was 17.8 months compared to 15.2 
months for the patients initially treated 
with placebo (p < 0.146). The estimated 
overall survival for the placebo-treated 
patients was 14.3 months.  
Sorafenib is considered a second line 
therapy and the suggested dose is 800 mg 
a day. Adverse effects were skin rash, 
hand-foot skin reaction, and fatigue. 
Discontinuation of the treatment was 
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           Figure 1. Targeted therapies for metastatic renal cell carcinoma and their mode of action. 
 
required in 9% of patients, and no deaths 
were reported due to toxicity of the 
treatment (10). Sorafenib was the first anti-
angiogenic multi-tyrosine kinase inhibitor 
for mRCC approved by the FDA (2005).  
 
Sunitinib  
 
Sunitinib is also an inhibitor of VEGFR1-3, 
c-kit, FLT-3 and PDGFR. Sunitinib has 
direct antitumor and anti-angiogenic 
activity (10, 11). This drug was approved by 
the FDA in 2006 and is now considered a 
first-line therapy for mRCC.  It is orally 
administered with the recommended daily 
dose of 50 mg/day by a schedule 4/2.  
 
In a phase III trial comparing sunitinib to 
interferon, the sunitinib arm showed 
doubled progression-free survival (PFS), 
improving PFS from 5 months with 
interferon to 11 with sunitinib as 
monotherapy. The objective response rates 
were 47% and 12% for sunitinib and 
interferon-α, respectively (P <0.001) and 
the median overall survival was 26.4 
months for sunitinib and 21.8 months for 
interferon-α (P = 0.051) (12). Moreover, 
access expanded globally, and another 
phase III trial was designed to provide 
sunitinib on relatively unselected or trial-
ineligible patients with brain metastases 
and poor ECOG performance status. 
Treatment with sunitinib demonstrated a 
PFS of 10.9 months and median overall 
survival of 18.4 months with similar overall 
survival in patients with and without prior 
cytokine therapy. Sunitinib did not present 
high severity adverse events, but 
hypertension, fatigue, diarrhea, and hand-
foot syndrome were described during 
treatment with this drug. Sunitinib was 
compared with IFN-α regarding quality-
adjusted time without symptoms of disease 
progression or toxicity of treatment (Q-
TWiST score). Sunitinib resulted in better 
clinical efficacy and quality-of-life outcomes 
compared with IFN-α for mRCC patients 
(13).  
 
Pazopanib  
 
Pazopanib is a second generation, orally 
administered multi-target tyrosine kinase 
receptor inhibitor that blocks VEGFR1-3, 
RET, and c-kit receptors (11-13).  A 
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Table 1: Angiogenesis/VEGF inhibitors: dose, molecular target and PFS outcome 
Therapy Dose Target Line of Therapy Study 
PFS 
(months) 
 
Ref 
 
Sorafenib 
 
Oral; 
400mg BID 
 
Raf-1 
serine/threoni
ne kinase, B-
Raf, VEGFR-2, 
PDGFR. C_KIT 
 
Second Linecyto 
 
Sorafenib v. 
Placebo 
5.5 v. 2.8* (10) 
Sunitinib 
 
Oral;  
50mg qd 
 
VEGFR1-3, c-
KIT, FLT3 
PDGFR 
First Line Sunitinib v. IFN 11 v. 5* (11) 
Pazopanib 
 
Oral;  
800mg qd 
VEGFR1-3; 
RET, c-kit 
First Line 
Pazopanib v. 
Sunitinib 
8.4 v. 9.5 (15) 
First Line 
Pazopanib v 
Placebo 
11.1 v. 2.8* (14) 
Second Line 
Pazopanib v 
Placebo 
7.4 v. 4.2* (17) 
Axitinib 
Oral;  
5mg tid 
VEGFR1 
First Line 
Axitinib v. 
Sorafenib 
10.1 v. 6.5* (19) 
Second Linecyto, 
vegf, mtor 
Axitinib v. 
Sorafenib 
6.7 v. 4.7* (18) 
Cediranibi 
Oral; 
45mg tid 
VEGF1-3 First Line 
Cediranib v. 
Placebo 
12.1 v. 2.8* (22) 
Bevacizu
mab-IFN 
IV; 
10mg/Kg 
2/2weeks 
VEGF First Line 
Bevacizumab-
IFN v IFN 
8.5 v. 5.2* (26) 
Bevacizumab-
IFN v IFN 
10.2 v. 5.4* (25) 
Bevacizu
mab-
Erlotinibi 
Oral; 
150mg qd 
EGFR tyrosine 
kinase 
First Line 
Bevacizumab-
Erlontinib v 
Bevacizumab 
9.9 v. 8.5 (28) 
PFS, progression free survival; i, investigational drug; cyto, post-cytokine; vegf, post-VEGF; mtor, 
post-mTORi; * statistically significant. 
 
 
randomized phase III trial comparing 
pazopanib with placebo showed a 
signiﬁcant improvement in PFS and tumor 
response in treatment-naïve metastatic 
RCC patients (54%) and previously 
cytokine-treated patients (46%). Compared 
to placebo, the overall PFS was 9.2 months 
for the pazopanib group vs 4.2 months for 
placebo patients (HR: 0.46; 95% CI: 0.34-
0.62; p<0.0001). In the treatment-naïve 
subpopulation, PFS was 11.1 months vs 
2.8 months (HR: 0.40; 95% CI: 0.27-0.60; 
p<0.0001) for pazopanib and placebo, 
respectively. In patients pretreated with 
cytokine, PFS was 7.4 months vs 4.2 
months (HR: 0.54; 95% CI: 0.35-0.84; 
p<0.001) for pazopanib and placebo, 
respectively (14).  
Another non-inferiority randomized phase 
III trial compared pazopanib with sunitinib.  
PFS and OS of pazopanib were not inferior 
to sunitinib, and quality of life with 
pazopanib was statistically better than 
sunitinib in those patients (15). Pazopanib 
demonstrated acceptable safety and 
tolerability even though it has been 
associated with liver toxicity. Common 
adverse events reported with pazopanib 
were hair color changes, nausea, anorexia, 
and vomiting while Grade 3-4 toxicity 
effects were hypertension, diarrhea, and 
liver toxicity (14). Pazopanib was approved 
by the FDA in 2009. It is considered as a 
first-line treatment and an option as a 
second-line treatment in previously 
cytokine-treated patients (16, 17). 
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     Table 2:  m-TOR inhibitors: dose, molecular target and PFS outcome 
    PFS, progression free survival; vegf, post-VEGF; * statistically significant. 
      
 
 
Pazopanib is usually administered orally at 
800 mg daily.  
 
Axitinib  
 
Axitinib is another second-generation 
inhibitor of VEGFR-1 which also has 
minimal effect on other targets. Axitinib is 
a second-line therapy option in cytokine-
refractory metastatic RCC. A Phase III 
clinical trial (18) that compared axitinib 
and sorafenib in 723 patients who were 
previously treated unsuccessfully with 
cytokine or VEGF inhibitors showed a 
median PFS of 6.7 months for the axitinib 
group and 4.7 months for the sorafenib 
group (p<0.0001). The OS was 29.9 months 
with a TTP of 15.7 months.  
 
The overall response rate was 22.6%, and 
the median duration of response was 17.5 
months. The adverse events of axitinib 
included diarrhea, hypertension, fatigue, 
dysphonia, and hand-foot syndrome (19). 
Grade 3 to 4 adverse events included hand-
foot syndrome, fatigue, hypertension, 
dyspnea, diarrhea, dehydration, and 
hypotension. Axitinib was approved by the 
FDA in 2012. Its potency is 50 to 450 times 
greater than the ﬁrst-generation VEGFR 
inhibitors (20, 21). The recommended dose 
of axitinib is 5.0 mg twice a day (18).  
 
Cediranib  
 
Cediranib is an ATP-competitive inhibitor of 
receptor tyrosine kinases (RTKs) related to 
VEGF1-3 (11). A phase II trial compared 
the efficacy of cediranib with placebo in 
patients with metastatic or recurrent clear 
cell RCC who had not previously received a 
VEGF signaling inhibitor. Partial responses 
were achieved in 34% patients, and 47% 
experienced a stable disease. PFS 
signiﬁcantly improved when compared to 
placebo with median 12.1 versus 2.8 
months (p = 0.017) (22). In addition, more 
than 50% of patients who achieved a 
partial response with cediranib experienced 
responses lasting more than a year. The 
most common adverse effects in patients 
were diarrhea, fatigue, hypertension, and 
dysphonia (23). The recommend dose is 45 
mg/day. Cediranib is still an 
investigational drug under the FDA.  
 
Bevacizumab  
 
Bevacizumab is a humanized recombinant 
IgG monoclonal antibody that binds to 
VEGF-A, increasing vascular permeability 
and reducing proliferation and migration of 
endothelial cells. The AVOREN (phase III) 
double-blind trial randomized 649 naïve 
patients to receive bevacizumab (10 mg/kg 
every 2 weeks) plus IFN-α (9 MUI) or 
placebo and IFN-α. The median overall 
response (OR) and stable disease in the 
bevacizumab plus IFN-α versus placebo 
plus IFN-α arms were 31 and 46% versus 
13 and 50%, respectively. PFS was 
significantly longer in the bevacizumab and 
IFN-α (10.2 versus 5.4 months; p<0.0001), 
but only in good-risk and intermediate-risk 
patients. In poor-risk patients, 
bevacizumab did not present any benefits 
(24).  
 
After progression, crossover was performed 
and the median OS was 23.3 months for 
bevacizumab-IFN-α vs 21.3 months for 
IFN-α alone (p=0.336) (25). Fatigue, 
Therapy Dose Target Line of Therapy Study 
PFS 
(months) 
Ref 
Temsirolimus 
IV; 
25mg 
weekly 
mTOR; 
HIF1-2; 
VEGF 
First Line 
Temsirolimus v 
IFN 
10.9 v. 7.3* (38) 
Second Linevegf 
Temsirolimus v 
Sorafenib 
4.3 v. 3.9 (45) 
Everolimus 
Oral; 
10mg 
Qd 
 
mTOR; 
HIF1;VEGF 
Second/Third 
Linevegf 
Everolimus v. 
Placebo 
4.9 v. 1.9* (36) 
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asthenia, and proteinuria were the most 
common grade 3 toxicities (11, 26). FDA 
approved bevacizumab in 2009 at 10 
mg/kg IV every 2 weeks in combination 
with IFN-α.  
 
Another  phase III (CALGB 90206)(26) 
randomized trial enrolled 732 previously 
untreated metastatic RCC patients for 
bevacizumab (10 mg/kg each 2 weeks) plus 
IFN-α (9 million U/3 times weekly) versus 
IFN-α monotherapy. PFS was 8.5 months 
for the combination compared to 5.2 
months for INF-α alone. After crossover, 
median OS was 18.3 for the combination 
compared to 17.4 for IFN-α alone. OR with 
bevacizumab plus IFN-α was higher 
compared to IFN monotherapy (25.5 vs 
13.1% p< 0.0001). The combination 
therapy was associated with higher grade 3 
to 4 hypertension (HTN), anorexia, fatigue, 
and proteinuria.  
 
Erlotinib  
 
Erlotinib inhibits the tyrosine kinase 
domain of epidermal growth factor receptor 
(EGFR), leading to the inhibition of EGFR 
auto-phosphorylation and downstream 
signaling (27). Erlotinib demonstrated 
encouraging activity in renal cell carcinoma 
when associated with bevacizumab in a 
phase II trial (28). 63 patients with 
metastatic clear-cell RCC were treated with 
bevacizumab at 10 mg/kg every 2 weeks 
and erlotinib at 150 mg/daily. Objective 
responses were achieved in 25% of the 
patients, disease was stable in 61% after 8 
weeks, and survival at 18 months was 
60%.  Another randomized double-blind 
phase II trial compared the combination of 
erlotinib and bevacizumab with 
bevacizumab alone. Combined therapy did 
not provide additional benefits when 
compared to bevacizumab alone (29).  
 
The combination of erlotinib with sirolimus 
in metastatic RCC did not show benefits 
when compared to a single agent in a 
phase II trial (30). 25 patients previously 
treated with sunitinib and/or sorafenib 
were evaluated and included. Partial 
responses or complete responses were 
observed; however, stable disease was 
noted in 21.8% of patients in 46 months. 
The progression-free survival and overall 
survival were 12 and 40 weeks respectively. 
Currently, Erlotinib is not approved by the 
FDA for the treatment of metastatic RCC.  
 
Mammalian Target of Rapamycin 
(mTOR) Inhibitors  
 
Another signaling pathway that is critical 
for cellular growth, proliferation, and 
angiogenesis is the mammalian target of 
rapamycin (mTOR) pathway (31). This 
pathway is more significantly mutated in 
clear-cell RCC, high-grade tumors, and 
tumors with poor prognostic features (32, 
33). A list of novel therapeutics targeting 
the mTOR pathway is summarized in Table 
2.  
 
Everolimus  
 
Everolimus is an mTOR inhibitor used in 
the treatment of VEGF- refractory disease. 
A phase II trial was conducted using 
everolimus at a daily dose of 10 mg for a 
28-day cycle in 41 patients with metastatic 
RCC who were previously treated with one 
therapy at most.  Median progression-free 
survival of 11.2 months and median overall 
survival of 22.1 months was reported (34). 
Partial responses were observed in 5 
patients, stable disease lasting 3 months 
was reported in 27 patients, and stable 
disease lasting 6 months was reported in 
21 patients.  
 
Another phase II trial in metastatic RCC 
patients who hadn’t received previous 
treatment or who had failed RCC treatment 
on sunitinib and/or sorafenib 
demonstrated anti-tumoral activity with the 
combination of everolimus and 
bevacizumab. Bevacizumab was given at 10 
mg/kg intravenously every 2 weeks and 
everolimus at 10 mg per day, orally. The 
median PFS in previously untreated 
patients was 9.1 months and 7.1 months 
in previously treated patients (35).  
 
A placebo-controlled phase III trial was 
designed with everolimus as a second-line 
therapy for advanced clear cell carcinoma 
refractory to sunitinib, sorafenib, or both 
agents. 410 patients were randomized to 
receive everolimus or placebo. Patients 
were stratified according MSKCC (Memorial 
Sloan-Kettering Cancer Center) prognostics 
score and whether they had previously 
received one or two VEGF receptor tyrosine 
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kinase inhibitors. PFS was significantly 
prolonged for everolimus by 4.9 months 
when compared to 1.87 months with 
placebo (36). Common adverse effects 
reported were stomatitis, rash, diarrhea, 
and non-infectious pneumonitis. 
Everolimus was approved by the FDA in 
2009 as an option for advanced RCC 
patients who had failed treatment with 
VEGF therapy. The usual dose is 10 mg 
once daily (37).  
 
Temsirolimus 
 
Temsirolimus is a specific inhibitor of 
mTOR and inhibits tumor angiogenesis by 
reducing synthesis of VEGF. Temsirolimus 
and IFN-α were used in a phase I/II Trial 
(38) for advanced RCC. 71 RCC patients 
were eligible and the recommended doses 
for temsirolimus was 15 mg and IFN-α was 
6 million units. Among patients who 
received the recommended dose, 8% 
achieved partial response, 36% had a 
stable disease for 24 weeks, and the 
median overall progression-free survival 
was 9.1 months.  
 
A phase III trial with 626 advanced and 
poor prognosis patients established that 
temsirolimus in combination with 
interferon did not improve survival (39). 
Overall survival medians in the interferon, 
temsirolimus, and combination groups 
were 7.3, 10.9, and 8.4 months, 
respectively. Monotherapy with 
temsirolimus showed longer overall 
survival and progression-free survival 
(P<0.001) than patients who received 
interferon alone (P<0.001). The median OS 
of temsirolimus and IFN-α as 
monotherapies were 10.9 and 7.3 months 
respectively. The median PFS time for the 
temsirolimus was 5.5 months compared 
with 3.1 months on IFN-α (p = 0.001).  
 
Common adverse events were rash, 
peripheral edema, hyperglycemia, and 
hyperlipidemia in the temsirolimus group 
whereas asthenia was more significant in 
the interferon group. Grade 3 or 4 toxicity 
occurred in almost 90% of patients in the 
combination therapy. Temsirolimus was 
approved by the FDA in 2007 for 
advanced/metastatic RCC patients with 
three or more poor prognostic features. The 
standard dose is 25 mg IV/weekly.  
Non-clear cell histology  
 
Presently, there is a lack of phase III trials 
on systemic treatment of patients with non-
clear cell RCC. Small studies for papillary 
type 1 and 2 were performed with sunitinib 
and everolimus, but none of them were 
prospectively randomized (40, 41). A phase 
II trial in patients with papillary RCC 
treated with foretinib (multikinase 
inhibitor) showed a median PFS of 9.3 
months and 13% response rate. The 
presence of germ line MET mutation was a 
strong predictor of a response (42). There is 
a lack of data to support systemic therapy 
in patients with collecting-duct subtype. 
These tumors have been included in 
prospective trials but with smaller numbers 
of patients, invalidating any type of 
analysis (43). 
 
Cytoreductive Nephrectomy in target 
therapy era 
 
Cytoreductive nephrectomy has been 
shown to extend overall patient survival in 
the multimodal treatment of metastatic 
RCC comparing  immunotherapy alone or 
combined with cytoreductive nephrectomy 
(44). In this target therapy era, it’s likely to 
remain part of the treatment and is 
recommended when possible. Complete 
removal of metastasis contributes to 
improved clinical prognosis and should be 
considered when feasible (2). 
 
Conclusion  
 
A better understanding of the tumor 
biology and the development and approval 
of multiple targeted agents for treatment of 
advanced RCC enables improved survival 
in patients with metastatic RCC. The 
standard of care in metastatic RCC is use 
of drugs that target VEGF and mTOR 
pathways. The third generation of tyrosine 
kinase inhibitors appears to have similar or 
superior efficacy as well as lower toxicity 
than existing agents.  
 
Compared to previous systemic therapies, 
these drugs showed evident clinical 
benefits. They increase progression-free 
overall survival and improve the quality of 
life, but complete responses have been 
rarely noted. Some questions have yet to be 
answered and demand more debate. The 
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most efficacious sequence of therapies and 
time to start a second-line agent (before or 
not progression of the disease) should be 
addressed in further studies.  
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